Therapeutic Development Services
Mantle cell lymphoma (MCL) in humans has the genetic trait of overexpressing D-type cyclins. At Protheragen, there is a specialized cadre of researchers and scientists well-versed in MCL. They are completely devoted to enhancing the development of novel treatment solutions for MCL, directed at addressing therapeutic gaps, advancing the innovations in medicine, and broadened targeted therapy.
Mantle cell lymphoma (MCL) represents a rare but aggressive form of B-cell non-Hodgkin lymphoma (NHL) and comprises approximately 6% of all cases of NHL. It mostly impacts the elderly population (median age at diagnosis: ~65 years) with a striking male predominance. MCL is clinically marked by diffuse lymph node enlargement, enlargement of the spleen, and frequent invasion of extranodal sites like the gastrointestinal tract and bone marrow.
Fig.1 Model of mantle cell lymphoma (MCL) pathogenesis. (Bödör, Csaba, and Lilla Reiniger., 2016)
The hallmark genetic alteration in mantle cell lymphoma (MCL) is the t(11;14)(q13;q32) translocation, present in >95% of cases. This translocation places the CCND1 gene under the control of the immunoglobulin heavy chain (IgH) enhancer, leading to constitutive overexpression of cyclin D1, a key regulator of the G1/S cell cycle transition. Cyclin D1 binds cyclin-dependent kinases (CDK4/6), promoting phosphorylation of the retinoblastoma (Rb) protein and facilitating uncontrolled proliferation.
Fig.2 Schematic diagram of the pathological mechanism of mantle cell lymphoma (MCL). (Klener, Pavel., 2019)
| Therapy | Mechanism of Action | Targets | NCT Number | Research Phase |
|---|---|---|---|---|
| Lenalidomide | Enhances T/NK cell-mediated cytotoxicity and inhibits angiogenesis. | CK1α/CRBN/IKZF1/IKZF3 | NCT00875667 | Approved |
| Bortezomib | Prevents degradation of pro-apoptotic proteins. | 26S proteasome | NCT00114738 | Approved |
| Venetoclax | Restores apoptosis in malignant B-cells. | BCL-2 protein | NCT06558604 | Phase II |
| LOXO-305 | Blocks BTK signaling, overcoming resistance to covalent BTK inhibitors. | Bruton's tyrosine kinase (BTK) | NCT04662255 | Phase III |
| Ibrutinib + Rituximab | Blocks BCR signaling and depletes B-cells. | BTK/CD20 | NCT05564052 | Phase II/III |
Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
To advance the effective management of mantle cell lymphoma (MCL), Protheragen offers comprehensive diagnostic and therapeutic development services. With a focus on the diverse molecular mechanisms driving MCL, we are dedicated to developing innovative and targeted therapies that address the significant unmet medical needs. Our team excels in creating highly accurate disease models, enabling rigorous evaluation of the safety, efficacy, and mechanism of action of potential therapeutics.
Therapeutic Development Services
As a leading provider of therapeutic development services, Protheragen is focused on developing a variety of innovative therapies for mantle cell lymphoma (MCL) to address the complex challenges in this field.
Animal models are essential tools for understanding the biology of mantle cell lymphoma (MCL) and evaluating the efficacy and safety of potential therapies.
At Protheragen, we are committed to supporting the development of innovative therapeutics through comprehensive preclinical research services, including pharmacodynamics (PD), pharmacokinetic (PK) and toxicology studies. Our customized approach addresses the unique challenges of your studies and helps you optimize your drug candidates for commercial success. If you are interested in our services, please feel free to contact us for more details and quotation information of related services.
References
Myeloproliferative Disorders (MPDs)
Bone Marrow Failure Syndromes (BMFS)
